Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

ABSTRACT:

Background

There is limited data on the clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in a real-world setting for Chinese patients with advanced ALK+ NSCLC.

Methods

The medical records of patients who received sequential therapy with first-line crizotinib followed by alectinib (no intermittent systemic therapy was allowed between the two ALK-TKIs) were collected from six centers in China. Combined time treatment to failure (C-TTF) was defined as the period from the start of crizotinib to the complete discontinuation of alectinib due to any cause.

Results

A total of 61 patients were included in our study. Fifty-two patients were switched to alectinib due to disease progression, seven as a resu

SUBMITTER: Zou Z 

PROVIDER: S-EPMC8720624 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature